Outcome of Board Meeting held on 28th November 2025, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Kabra Drugs Ltd met on 28 November 2025 and approved several key items. Two new Non-Executive Independent Directors have been recommended for appointment: Ms. Ritu Tiwari and Ms. Nikita Sinha. The company also approved signing an agreement with M/s. MR Franchise to onboard 200 channel partners across India, with Managing Director Mr. Nanjappan Aravind authorized to execute the deal. An Extra-Ordinary General Meeting (EGM) has been scheduled for 26 December 2025 in Indore, with M/s. Jay Jain & Associates appointed as Scrutinizer. Additionally, the board noted the resignation of Secretarial Auditor Mr. Tanuj Jain Susilkumar and approved the appointment of Mrs. Twinkle Agarwal as the new Secretarial Auditor for five financial years (FY2025-26 to FY2029-30). Remuneration of Mr. Kuniamuthur Nanjappan Anand was also revised.
For shareholders, the appointment of two independent directors strengthens board composition, while the 200 channel partner expansion signals a push to grow distribution. The mid-term change of Secretarial Auditor is a routine compliance matter. The EGM on 26 December may include items requiring shareholder voting, so investors should watch for the notice.